Stockscreener 앱 받기
3.09
1.59%
-0.05
시간 외 거래:
3.09
전일 마감가:
$3.14
열려 있는:
$3.19
하루 거래량:
305.03K
Relative Volume:
0.78
시가총액:
$260.99M
수익:
$351.37M
순이익/손실:
$-174.01M
주가수익비율:
-1.4928
EPS:
-2.07
순현금흐름:
$-126.94M
1주 성능:
-1.90%
1개월 성능:
-4.63%
6개월 성능:
-19.11%
1년 성능:
-26.60%
1일 변동 폭
$3.05
$3.19
1주일 범위
$3.04
$3.235
52주 변동 폭
$2.75
$4.60
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
명칭
Atea Pharmaceuticals Inc
전화
857-204-8109
주소
225 FRANKLIN STREET, BOSTON
AVIR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.09 | 260.99M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-13 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-10-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | 개시 | Evercore ISI | Outperform |
| 2020-11-24 | 개시 | JP Morgan | Overweight |
| 2020-11-24 | 개시 | Morgan Stanley | Overweight |
| 2020-11-24 | 개시 | William Blair | Outperform |
모두보기
Atea Pharmaceuticals Inc 주식(AVIR)의 최신 뉴스
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Wednesday - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) versus Atea Pharmaceuticals (NASDAQ:AVIR) Critical Survey - Defense World
Peapod Lane Capital LLC Acquires New Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Stocks of Atea Pharmaceuticals Inc (AVIR) are poised to climb above their peers - SETE News
Roche Walks Away From Atea Partnership To Develop COVID Pill - BW Healthcare World
February 2025 US Penny Stocks To Watch - Simply Wall St
Director BERGER FRANKLIN M sale 359,606 shares of Atea Pharmaceuticals Inc [AVIR] - Knox Daily
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Update - MarketBeat
JPMorgan Chase & Co. Grows Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals director Franklin Berger acquires $81,498 in stock - MSN
Short Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Decreases By 12.9% - MarketBeat
Franklin Berger Increases Stake in Atea Pharmaceuticals Inc (AVI - GuruFocus.com
Barclays PLC Buys 75,624 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Barclays PLC Has $593,000 Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Atea Pharmaceuticals Targets $3B HCV Market with Phase 3 Trial Launch, Backed by $454M Cash - StockTitan
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Atea Pharmaceuticals CEO to Present Business Update at J.P. Morgan Healthcare Conference - StockTitan
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stock Position Decreased by Geode Capital Management LLC - Defense World
Barclays PLC Increases Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
State Street Corp Purchases 11,566 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
US Penny Stocks To Watch In December 2024 - Simply Wall St
Atea Pharmaceuticals Faces Shareholder Revolt Over Director's Stock Sale, Strategic Decisions - StockTitan
Atea Pharmaceuticals engages Evercore to explore partnerships - MSN
Analyzing Atea Pharmaceuticals (NASDAQ:AVIR) & Alnylam Pharmaceuticals (NASDAQ:ALNY) - Defense World
Atea Pharmaceuticals, Inc. Engages Evercore to Identify Potential Opportunities to Enhance Shareholder Value, Including the Exploration of Strategic Partnerships Related to Its Phase 3-Ready Program for the Treatment of Hepatitis C Virus - Marketscreener.com
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships - GlobeNewswire
Atea Pharmaceuticals Taps Evercore to Explore Strategic Options for Phase 3 HCV Program - StockTitan
Charles Schwab Investment Management Inc. Acquires 50,794 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals director Franklin Berger sells $1.02 million in stock By Investing.com - Investing.com Nigeria
Atea Pharmaceuticals director Franklin Berger sells $1.02 million in stock - Investing.com
Fmr LLC Buys 182,174 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Atea Pharmaceuticals stock hits 52-week low at $2.88 By Investing.com - Investing.com Australia
Atea Pharmaceuticals stock hits 52-week low at $2.88 - Investing.com
Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir - Yahoo Finance
Atea Aims For Underserved HCV Niche With Combo Regimen - News & Insights
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study - Yahoo Finance
Atea reports high efficacy in Phase 2 HCV treatment study - Investing.com
Atea Pharmaceuticals Announces Positive Results from Phase - GlobeNewswire
Atea's HCV Drug Achieves 98% Cure Rate in Phase 2 Trial, Shows Breakthrough Promise - StockTitan
Atea plans Phase 3 study for hepatitis C drug after mid-stage results - Yahoo Finance
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference - GlobeNewswire
Atea Pharmaceuticals CEO to Present at Evercore HealthCONx Conference | AVIR Stock News - StockTitan
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? - MSN
Island Pharmaceuticals Advances Dengue Clinical Trial - MSN
Atomo Diagnostics Plans Share Issuance to Boost Capital - MSN
Atea Pharmaceuticals Inc (AVIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):